Evidence map›Paper›PMID 41961754›Full record

ArticleEndocrine-related cancer2026

Proteomic signatures of adipocyte recruitment in breast cancer.

Dimitrios G Argyris, Ioanna Ploumaki, Theodora Argyri, Dimitra P Anastasiadou, Nikos S Karagiannis, Maria P Pavlou, Evanthia T Roussos Torres, Outhiriaradjou Benard, Rachel B Hazan, Panagiota S Filippou and 1 more

Abstract read
In one paragraph

Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dimitrios G ArgyrisDepartment of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Ioanna Ploumaki4th Department of Internal Medicine, Medical School, University General Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece.
Theodora ArgyriSchool of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitra P AnastasiadouDepartment of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Nikos S KaragiannisGruss Magnetic Resonance Research Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Maria P PavlouProteomics Core Facility, École Polytechnique Fédérale de Lausanne, School of Life Sciences, Lausanne, Switzerland.
Evanthia T Roussos TorresDepartment of Medicine, Division of Medical Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
Outhiriaradjou BenardDepartment of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA.
Rachel B HazanDepartment of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA.
Panagiota S FilippouLaboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
George S KaragiannisDepartment of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0002-8808-707X

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
High Speed, High Resolution Slide Scanner for Research in Translational MedicineS10OD026852 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CONDEELIS, JOHN S · 2022 to 2022
$472k
NCI NIH HHS P30 CA013330NIH HHS S10 OD026852
6 · The paper itself

Abstract

The tumor microenvironment (TME) is increasingly recognized as a dynamic regulator of breast cancer progression, with adipocytes functioning as active contributors rather than passive bystanders. Here, we investigated the proteomic and morphologic reprogramming of breast cancer-associated adipocytes (BrCAAs) in response to triple-negative breast cancer (TNBC). Using conditioned medium from HCC1143 cells, we established an in vitro BrCAA model and performed mass spectrometry-based proteomics. Comparative profiling revealed 256 differentially expressed proteins, enriched for pathways including fatty acid degradation, carbon metabolism, and glycogen turnover, consistent with a metabolic shift from energy storage to energy supply. Gene ontology and protein-protein interaction analyses further identified cytoskeletal remodeling, adhesion dynamics, and secretory pathway activation, supporting BrCAA-driven microenvironmental remodeling. In the MMTV-PyMT mouse model, morphometric analysis demonstrated progressive size reduction and increased contour irregularity of adipocytes adjacent to tumors, correlating with proteomic evidence of metabolic stress. Importantly, BrCAAs localized at tumor interfaces were associated with increased microvessel density and CD105+ endothelial activation compared to desmoplastic zones. Proteomic enrichment highlighted pro-angiogenic remodeling, with validation of basigin (BSG), integrin αV (ITGAV), and 2,4-dienoyl-CoA reductase 1 (DECR1). Collectively, our findings establish BrCAAs as metabolically and structurally reprogrammed stromal components that promote tumor metabolism and localized angiogenesis, representing potential therapeutic targets in aggressive breast cancer.

Indexed as

AdipocytesBreast NeoplasmsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansMetabolic ReprogrammingMiceProteomicsTumor Microenvironmentangiogenesisbreast cancercancer-associated adipocytesmetabolic reprogrammingproteomicstumor microenvironment

Identifiers

PMID41961754
PMCPMC13147392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.